IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 224 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $265,816 | +120178.7% | 37,758 | +3.8% | 0.00% | 0.0% |
| Q1 2023 | $221 | +0.9% | 36,373 | +5.8% | 0.00% | 0.0% |
| Q4 2022 | $219 | -99.9% | 34,373 | +11.3% | 0.00% | -50.0% |
| Q3 2022 | $295,000 | -15.0% | 30,873 | -2.2% | 0.00% | 0.0% |
| Q2 2022 | $347,000 | -8.0% | 31,555 | +39.1% | 0.00% | 0.0% |
| Q1 2022 | $377,000 | -13.9% | 22,684 | -1.3% | 0.00% | 0.0% |
| Q4 2021 | $438,000 | +5375.0% | 22,992 | +6469.1% | 0.00% | – |
| Q3 2021 | $8,000 | -38.5% | 350 | -30.0% | 0.00% | – |
| Q2 2021 | $13,000 | -13.3% | 500 | 0.0% | 0.00% | – |
| Q1 2021 | $15,000 | -34.8% | 500 | 0.0% | 0.00% | – |
| Q4 2020 | $23,000 | -23.3% | 500 | -45.2% | 0.00% | – |
| Q3 2020 | $30,000 | +25.0% | 912 | +5.7% | 0.00% | – |
| Q2 2020 | $24,000 | -14.3% | 863 | -7.2% | 0.00% | – |
| Q1 2020 | $28,000 | +33.3% | 930 | +24.0% | 0.00% | – |
| Q4 2019 | $21,000 | +2000.0% | 750 | +814.6% | 0.00% | – |
| Q1 2019 | $1,000 | – | 82 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |